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ABSTRACT
Evidence suggests that 15-lipoxygenase-2 (15-LOX-2) plays an important role in
the progression of atherosclerosis. Due to the medical need to discover isoform specific
inhibitors of 15-LOX-2, a novel human enzyme, our goal was to determine the 3dimensional structure. Using bacterial expression, we were able to obtain a usable
quantity of enzyme with a sufficient amount of the catalytic iron bound to the enzyme,
however it was sensitive to cleavage by proteases. This led to a ratio of roughly 1:1 of
cleaved and uncleaved protein after the final step of purification. Solving the crystal
structure revealed the reason for the protease sensitivity. In the polycistin-1
lipoxygenase alpha-toxin (PLAT) domain of the protein there is a large loop composed
of nonpolar amino acids, which is flanked by calcium ions. The next step was to
determine the purpose of calcium binding. Analytical size exclusion chromatography
(SEC) experiments revealed that when calcium binding sites were mutated, the enzyme
could not bind the synthetic phospholipid bilayer mimic, nanodiscs, which indicated that
calcium is necessary for membrane binding.
In the crystal structure, the active site of 15-LOX-2 contained a detergent
molecule, C8E4, which was necessary for crystallization. This detergent molecule was
later identified as a competitive inhibitor and its size and flexibility make it comparable to
the enzyme’s natural substrate arachidonic acid (AA). Comparison of the structure of
15-LOX-2 with the stable 5-LOX structure suggested that the 5-LOX active site is
occluded by the broken α2-helix and must open for substrate acquisition.
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This structure will provide information relevant to the design of isoform specific
inhibitors which will aid in determining the function of 15-LOX-2 and could result in the
development of therapeutic agents to protect against atherosclerotic plaque
development.
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CHAPTER ONE
LITERATURE REVIEW

BACKGROUND
Cholesterol is synthesized in the liver and is deposited in tissues via low-density
lipoproteins (LDL). LDL particles are comprised of a core of cholesteryl esters. The
exterior monolayer of phospholipids is wrapped with the apo-B100 protein to solubilize
the particle and interact with LDL receptors in non-hepatic cells. Normally, cholesterol
uptake is regulated via the SREBP-2 transcription factor. When there is low cholesterol
in the endoplasmic reticulum (ER), SREBP-2 is cleaved from its membrane tether,
allowing for the N-terminal domain to initiate transcription of proteins necessary for
cholesterol synthesis and uptake, including the LDL receptor (LDLR) (Luu, Sharpe,
Gelissen, & Brown, 2013). The LDLR binds to the apo-B100 protein on LDL particles
via its extracellular N-terminal domain so that the LDL can be engulfed by the cell. This
uptake, along with de novo synthesis of cholesterol, is used to increase the
concentration of cholesterol in the cell allowing for downstream utilization of cholesterol
in membrane and steroid synthesis.
The intracellular cholesterol concentration must be kept in balance. When the
cholesterol level is elevated in the cell, reverse cholesterol transport is stimulated by
liver X receptor (LXR) and retinoid X receptor (RXR) hetero-dimerization. Upon
dimerization the expression of ATP binding cassette transporters (ABCA1) and ABCG1
is increased, which prompts transport of cholesterol from the membrane to apo-A1 to
form nascent or discoid shaped high density lipoprotein (HDL and nHDL) (Nomiyama &
Bruemmer, 2008). Mature HDL are formed when cholesterol esters are formed. HDL
1

formation allows for the mobilization of cholesterol from the tissue back to the liver
where it can be excreted. However, HDL can be oxidized on the apo-A1 protein which
impairs reverse cholesterol transport, aiding atherosclerosis progression (Shao et al.,
2010).
Atherosclerosis is the slow accumulation of foam cells in the intima of blood
vessels. Over time these form fatty streaks, which grow into plaques capable of limiting
blood flow in the lumen. High LDL in the blood increases the amount of LDL infiltration
into the intima. This allows for the LDL to become oxidized and engulfed by
macrophages via scavenger receptors, forming foam cells. This triggers an
inflammation cascade that elicits a chemotactic response and adhesion molecule
expression, allowing for the monocytes to better infiltrate the endothelial barrier and
differentiate into macrophages. If the LDL concentration remains high over time, a state
of chronic inflammation develops, which allows for increased monocyte infiltration and
foam cell formation, resulting in the thickening of the intimal wall and further restriction
of blood flow (Swirski & Nahrendorf, 2013). Over time a fibrous cap will form over the
large plaque. This stabilizes the plaque and protects it from rupturing, which would lead
to thrombosis or embolism formation (Vijil, Hermansson, Jeppsson, Bergstrom, &
Hulten, 2014).
LIPOXYGENASE REVIEW
The discovery that oxidative modification of LDL led to the deregulated uptake of
LDL by macrophages via scavenger receptors made lipoxygenases (LOX) a logical
suspect in promoting atherosclerosis. Initial in vitro experiments showed that 15lipoxygenase-1 (15-LOX-1) could oxidize the polyunsaturated fatty acids (PUFA) in the
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cholesteryl ester fraction as well as the phospholipid portion of an LDL. Most of this
oxidation was found on linoleic acid that forms the stereospecific 13SHydroperoxyoctadecaenoic acid (13S-HPODE) after reduction. The biological
importance of these studies is unknown, because LDL is thought to be limited to the
extracellular space prior to oxidation and a secretion pathway for 15-LOX-1 has not
been elucidated. Further studies found that rabbit 15-LOX-1 mRNA and expression
was localized in fatty lesions of late stage atherosclerosis (Yla-Herttuala et al., 1990).
However, later work showed that the recently discovered 15-lipoxygenase-2 (15-LOX-2)
is expressed in human atherosclerotic plaques (Gertow et al., 2011; Hulten et al., 2010).
Activation of human monocytes with the anti-inflammatory cytokines, IL-6 and IL-13,
stimulates both 15-LOX-1 and 15-LOX-2 expression (Wuest, Crucet, Gemperle, Loretz,
& Hersberger, 2012). These findings support a role of 15-LOX-1 and 15-LOX-2 activity
in atherosclerosis, but they fail to determine what that role is.
Lipoxygenases are a family of nonheme iron containing enzymes, found primarily
in eukaryotes, which are capable of oxidizing polyunsaturated fatty acids (PUFA) to
form bioactive lipids. These enzymes are named for the location of oxygen addition
when arachidonic acid (AA) is the substrate. Plant LOX are larger, possessing roughly
20% more amino acids compared to animal LOX, and they metabolize linoleic or
linolenic acids (Brash, 1999). Despite this, animal LOX still retain structural similarity
with the plant LOX. Humans possess six enzymes that belong to the lipoxygenase
family. Five lipoxygenase (5-LOX), 12-lipoxygenase (12-LOX), 12R-lipoxygenase (12RLOX), 15-LOX-1, and 15-LOX-2; each has a distinct product profile and is regulated
differently. Most LOX are two domain proteins with a C2 like domain known as the
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polycystin-1 lipoxygenase alpha-toxin (PLAT) domain and the mostly alpha helical
catalytic domain. The active sites are mostly hydrophobic channels consisting of highly
conserved residues. The first animal LOX structure, rabbit 15-LOX-1, was interpreted to
contain a boot shaped active site (Gillmor, Villasenor, Fletterick, Sigal, & Browner,
1997). However mutagenesis combined with structural studies of coral 8R-LOX,
suggest the active site is more of a “U” shape, and subsequent studies with either
substrate (8R-LOX) or flexible inhibitors bound (15-LOX-2 and a porcine 12-LOX)
support the latter model (Kobe, Neau, Mitchell, Bartlett, & Newcomer, 2014; Neau et al.,
2014; Xu, Mueser, Marnett, & Funk, 2012). The U shaped channel is partly formed by a
π helix and the α2-helix. The conformation of the α2-helix is “broken” into a helix-turnhelix motif in the 5-LOX structure and a coral 11R-LOX structure resulting in entry to the
active site being blocked (Eek et al., 2012; Gilbert et al., 2011). The unbroken α2-helix
in other LOX allows the channel to be open and solvent accessible. These helices
allow for the substrate binding pocket to be positioned next the bound iron. Iron is
bound by three invariant histidine residues, an asparagine or histidine, the carboxyterminus, and a water molecule. These interactions allow for the octahedral
coordinated iron to be in position to initiate catalysis once oxidized. However, 15-LOX-2
possesses a serine bound to a water that helps coordinate the iron. Mutation of this
serine, in the mouse 8SLOX (an orthologue of 15-LOX-2), to histidine or asparagine
appear not to hinder catalysis, so the significance of this difference is still not
understood (Jisaka, Boeglin, Kim, & Brash, 2001).
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Figure 1: The different possible pentadienes available for hydrogen abstraction on AA. Each carbon
contains two hydrogens which represent the proS or proR hydrogen. The proS and proR hydrogens on
carbon 7 are inverted from the ones on carbon 10 and 13 because 5-LOX accepts AA headfirst (carboxyl
end) while 12S and 15-LOX-1 &15-LOX-2 accept AA tail first (methyl end). Oxygen addition occurs on
the opposite side of hydrogen abstraction..

The LOX enzymes have a common four-step reaction mechanism that starts with
oxidation of the ferrous iron to ferric. This is thought to be done by trace lipid
hydroperoxides (Haining & Axelrod, 1958). Hydrogen abstraction at a pentadiene
coupled with electron transfer to the ferric iron forms a radical on the PUFA. Next, due
to protein shielding, the radical rearranges two carbons away where an O2 molecule is
added and reduced to form the Hydroperoxyeicosatetraenoic acid (HPETE) (Glickman
& Klinman, 1996). HPETE can be further reduced to an alcohol by glutathione
peroxidase (GPx) to decrease radical formation due to homolytic cleavage. GPx is also
thought to regulate lipoxygenases by limiting the amount of trace lipid hydroperoxides in
the cell necessary for activation of the LOX (Weitzel & Wendel, 1993).

5

Figure 2: The different steps of the LOX reaction (adapted from Murphy & Gijon, 2007). (A) The
iron is oxidized from ferrous to ferric by a trace lipid hydroperoxide. (B&C) The hydrogen is abstracted,
reducing the iron. A proton is transferred to the OH-. (D) The radical rearranges, and oxygen is added at
the targeted carbon. (E) Oxygen is reduced to form a negative charge and oxidize the iron. (F) A proton
is accepted from a water molecule to form HPETE. (G) HPETE leaves the active site with the iron in the
active ferric form allowing another reaction to occur.

6

(Figure 2 continued)

Some PUFA such as linoleic acid (LA) contain a single pentadiene, but AA
possesses 3 pentadienes which allows for alternate product formation. Multiple factors
direct the regiospecific and stereospecific LOX reaction. Substrate orientation is
important because the correct pentadiene must be positioned next to the iron in the
active site. The M418V mutation in 15-LOX-1 allows for deeper penetration of the AA
into the nonpolar channel allowing for a switch between the major and minor products
because C10 is then favored for hydrogen abstraction over C13 (Sloane, Leung, Craik,
& Sigal, 1991). Also, oxygen addition occurs on the opposite side as hydrogen
abstraction, and LOX have the option to remove either a pro R or pro S hydrogen.
Coffa and Brash noticed that in a conserved position, the (S)-HPETE producing LOX
contains an Ala while the (R)-HPETE producing LOX possess a Gly. Mutations
changing the Ala to Gly or vice versa changed the stereochemistry and the position of
the oxygen moved to the opposite end of the activated pentadiene causing the 8R-LOX
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to act like a 12S-LOX. This is due to the position of the Ala close to the substrate,
which directs the tilt of the O2 (Coffa & Brash, 2004).
Charged residues have been observed to dictate head-first (carboxyl end) or tail
first (methyl end) orientation. Both 15-LOX accept AA tail first, but a V603H mutation of
15-LOX-2 to mimic the mouse 8SLOX resulted in the formation of 8S-HPETE in addition
to 15-HETE. (Walther et al., 2009). This is due to the addition of a positively charged
residue deep in the active site, which attracts the carboxyl head. The dual mutant
D602Y/V603H produced an even higher proportion more 8S-HPETE (Jisaka, Kim,
Boeglin, & Brash, 2000). The 15-LOX-2 structure suggest it is possible that the D602Y
disrupted the position of R429, a positively charged residue at the entrance to the active
site, by introducing a cation-pi interaction, disrupting a possible anchoring point for the
carboxylic acid head of AA.
FUNCTION OF 15-LOX-1
Multiple animal studies have tried to shed light on the function of 15-LOX-1 in
atherosclerosis with mixed results. In vivo and ex vivo studies have made use of mice
and rabbit models. Mice express an enzyme known as 12/15-LOX that has ~74%
sequence identity to human 15-LOX-1. Despite the sequence similarity, the enzyme’s
major product is 12-HPETE with a minor product of 15-HPETE. Mouse 12/15-LOX
produces these products in a 3:1 ratio compared to the 1:12 ratio produced by human
15-LOX-1 (Chen, Kurre, Jenkins, Copeland, & Funk, 1994; Kuhn et al., 1993). Despite
the differences in products, mice with various knockouts to simulate hypercholesteremia
or reduced LDL clearance (apoE-/- or LDLR -/-), have been used to investigate the
function of 15-LOX-1 in atherosclerosis.
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Mouse 12/15-LOX or the 12/15-LOX product stimulates adhesion of monocytes
to endothelial cells (Bolick, Srinivasan, Whetzel, Fuller, & Hedrick, 2006; Reilly et al.,
2004). Mice with 12/15-LOX and ApoE knockouts had smaller lesions and less LDL
oxidation after 15 weeks (Cyrus et al., 2001; Cyrus et al., 1999). Bone marrow
transplants from this mouse model to control mice resulted in reduced lesion
development suggesting that macrophage 12/15-lipoxygenase is integral for the
progression of atherosclerosis (Huo et al., 2004). However, a 12/15 knockout in a
mouse arthritis model suggests an anti-inflammatory role for 12/15-LOX due to
increased joint inflammation and damage. Knockouts with transgenic expression of
tumor necrosis factor α (TNFα) showed increased expression of inflammatory
interleukins (IL-1β) and IL-6. Ex vivo experiments of these 12/15-LOX -/- macrophages
revealed decreased LOX production (Kronke et al., 2009). Human 15-LOX-1
expression in mouse RAW macrophages increases expression of ABCA1 and reverse
cholesterol transport, which was blocked by treatment with probucol, an ABCA1
inhibitor. (Weibel et al., 2009).
Rabbits display an increased 13S-HODE: 13R-HODE ratio in aortic plaques,
which correlated with significant cholesterol deposited. Later in the study increased
13R-HODE formation was observed, but 13S-HODE was still favored (Kuhn, Belkner,
Zaiss, Fahrenklemper, & Wohlfeil, 1994). This suggests that 15-LOX activity, at least
initially, is involved in oxidizing LDL. A similar result was seen when human plaques
were used. Most plaques analyzed displayed a higher percentage of 13S-HODE when
compared to LDL treatment with copper used as a control to show non-specific
oxidation (Folcik, Nivar-Aristy, Krajewski, & Cathcart, 1995).
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Overexpression of rabbit 15-LOX-1 in anemic rabbits resulted in a decreased
level of lipids deposited in the aorta (Trebus, Heydeck, Schimke, Gerth, & Kuhn, 2002).
However, pharmacological inhibition of rabbit 15-LOX-1 with PD146176 resulted in less
advanced lesions compared to control rabbits (Sendobry et al., 1997).
Transgenic overexpression of human 15-LOX-1 in macrophages resulted in
smaller aortic lesions after feeding with a high fat, high cholesterol diet (Shen et al.,
1996). In an acute periodontitis model of inflammation, transgenic overexpression of
human 15-LOX-1 in rabbits decreased tissue damage and enhanced lipoxin (LX)
production. Ex vivo studies using the neutrophils from this model displayed a
decreased chemotactic response (Serhan et al., 2003).
FUNCTION OF 15-LOX-2
The recent discovery of 15-LOX-2 further complicated interpretation of the role of
15-LOX-1 in atherosclerosis (Brash, Boeglin, & Chang, 1997), however the function of
this enzyme seems to be more straightforward when compared to 15-LOX-1. 15-LOX-2
also oxidizes AA into 15-HETE, but initially it was not thought to be expressed in
macrophages. However, immunohistochemical analysis confirmed co-localization of
CD68, a macrophage marker protein and 15-LOX-2. Plaque macrophages highly
express 15-LOX-2 as confirmed by real time polymerase chain reaction. Oxygen
concentration has been shown to decrease as a plaque develops, creating a hypoxic
environment (Bjornheden, Levin, Evaldsson, & Wiklund, 1999). 15-LOX-2 can colocalize with hypoxia inducible factor-1α (HIF-1α) in plaques seen in patients with artery
blockage up to approximately 70% (Danielsson et al., 2008). Human macrophages
incubated in 1% oxygen to mimic a hypoxic environment showed increased 15-LOX-2
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expression. Incubation of macrophages with dimethyloxallyl glycine (DMOG), a prolyl
hydroxylase inhibitor, resulted in increased 15-LOX-2 expression. This result is
consistent with the reduced HETE secretion in hypoxia-inducible factor 1-alpha (HIF-1α)
knockdown macrophages (Hulten et al., 2010). THP-1 macrophages overexpressing
15-LOX-2 showed increased HETE formation and increased C-X-C motif chemokine 10
(CXCL10) expression, which has been shown to be a chemoattractant for the
inflammatory subtype M1 macrophages. Knockdown of 15-LOX-2 in mouse and human
macrophages resulted in increased lipid accumulation (Magnusson et al., 2012). Higher
expression of 15-LOX-2 has been linked to complicated lesions and thrombosis
formation since 15-HETE stimulates thrombin expression. This is due to its increased
expression in these plaques and stimulation of thrombin expression by 15HETE (Vijil et
al., 2014). This data suggest that 15-LOX-2 is important in the progression of
atherosclerosis.
MEMBRANE BINDING
Initially it was thought that AA had to be cleaved from the sn2 position of
phospholipids by cytosolic phospholipase a2 (cPLA2) for 15-LOX-2 to access its
substrate in the cytosol, yet it was found that in the presence of a calcium ionophore
(which stimulates cPLA2 release of AA) cytosolic 15-LOX-1 activity declined
(Bongrazio, Roscher, Ludwig, & Nigam, 1992). Using immunohistochemistry and cell
fractionation studies, it was found that calcium induced membrane binding by 15-LOX-1
in multiple cells, as well as its activity on the membrane phospholipids in the absence of
cPLA2 activity (Brinckmann et al., 1998). Since the PLAT domain is not necessary for
activity, it appears that the two distinct domains govern two distinct functions. The
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PLAT domain permits membrane binding while the α-helical domain is responsible for
catalysis (Walther, Anton, Wiedmann, Fletterick, & Kuhn, 2002; Xu et al., 2012).
Despite these results, the rabbit 15-LOX-1 structure does not show a bound Ca2+ ion
(Choi, Chon, Kim, & Shin, 2008). However, the protein does possess the same
structural motif as the calcium binding sites in the 15-LOX-2 structure (Kobe et al.,
2014). When 5-LOX binds the nuclear membrane, it co-localizes with its activating
protein. 5-LOX activating protein (FLAP) is necessary for the in vivo formation of LTA4.
15-LOX-1 can bind plasma membranes and oxidize ester linked PUFA without the
subsequent need for an activating protein, although, it is able to oxidize free AA.
Recently, analytical size exclusion chromatography experiments demonstrated 15-LOX2 ability to bind nanodiscs, soluble synthetic membranes (Schuler, Denisov, & Sligar,
2013), in the presence of calcium. It is unknown where 15-LOX-2 is sequestered upon
calcium stimulation, however preliminary results suggest that it binds the plasma
membrane (E. Schexnaydre personal communication). 15-LOX-2 is able to oxidize
detergent solubilized arachidonoyl phosphatidylcholine (Coffa & Brash, 2004). While
this along with membrane binding studies does not confirm membrane activity, it does
suggest that 15-LOX-2 is able to directly oxidize phospholipids at the bilayer.
THE FATE OF LOX PRODUCTS
Activated platelets form 12-HPETE esterified to phosphatidyl ethanolamine (12HPETE-PE), which then migrates to the outer leaflet of the plasma membrane (Thomas
et al., 2010). 12-HPETE-PE is produced in activated mouse monocytes, but human
monocytes produce both 15-HPETE-PE and 15-HPETE-PC with PE being the major
class of oxidized phospholipids. It has not been determined in which membrane leaflet
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15-HPETE-PE or 15-HETE-PC localize, but tandem mass spectrophotometry analysis
of cells compared to supernatant confirms it is mostly retained in the cell membrane
(Maskrey et al., 2007). It is tempting to speculate that these oxidized phospholipids at
the membrane could initiate non-enzymatic oxidation of LDL in the extracellular space.
This thinking would lead to a 1:1 ratio of (S)/(R) oxidized LDL which contradicts previous
HPLC experiments (Brinckmann et al., 1998) (Folcik et al., 1995). It has been shown
that mouse macrophages incubated together with liposomes containing cholesteryl
esters formed 15-LOX-1 specific oxidized PUFA on macrophage PC. This suggest that
there is some sort of acyl remodeling that allows for the movement of extracellular lipids
into intracellular lipid pools (Hutchins & Murphy, 2012).
Exogenously added 15-HETE is rapidly esterified into phosphatidylinositol (PI) in
human neutrophils, which results in decreased LTA4 production in cells and increased
LX production (Brezinski & Serhan, 1990). 15-HETE also makes neutrophils resistant
to LTA4 stimulated chemotaxis and adhesion while decreasing the affinity of LTB4 for its
receptor. (Takata et al., 1994). These anti-inflammatory actions of 15-HETE in
neutrophils are due to it also being an alternative substrate of 5-LOX, which forms 5-15DiHETE. Therefore LTA4 does not accumulate as rapidly and the inflammatory actions
of leukotrienes are not observed. (Petrich, Ludwig, Kuhn, & Schewe, 1996). Mouse
macrophages show esterification of 15-HETE on PI, PE, and PC (Pawlowski, Scott,
Andreach, & Cohn, 1982). When THP-1 macrophages were treated with exogenous
15-HETE an increased uptake of labeled oxidized LDL was observed. 12-HETE, 15RHETE and 15HETE were able to induce the expression of CD36, a scavenger receptor,
with 15HETE being the most potent activator of expression. Blocking translation of
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CD36 in 15HETE stimulated macrophages with antisense oligonucleotides decreased
foam cell formation (Kotla, Singh, Traylor, Orr, & Rao, 2014). The neutrophil
experiments suggest a protective effect against atherosclerosis due to the decreased
amount of inflammatory leukotrienes and increased anti-inflammatory LX produced.
However the increased expression of scavenger receptor CD36 suggests an
atherogenic function.
LIPOXIN FORMATION
At some time point it is necessary to turn off inflammation to decrease tissue
damage. At this point there is a class switch in the lipid mediators formed. Production
of inflammatory mediators decreases and anti-inflammatory molecules are made.
Treatment of neutrophils with Prostaglandin E2 initiated a switch from synthesis of LTB4,
to predominant synthesis of LXA4 (Levy, Clish, Schmidt, Gronert, & Serhan, 2001).
Lipoxygenases involved in the initiation of the inflammatory cascade are also involved in
the resolution of inflammation. Through the combined action of 5-LOX and either 15LOX or 12-LOX, LX are formed (Serhan, 2005). It is unclear whether 15-LOX-2 is
involved in LX synthesis. Multiple diseases such as cystic fibrosis and ulcerative colitis
display reduced 15-LOX-2 expression and reduced LX formation suggesting that the
two are correlated (Mangino, Brounts, Harms, & Heise, 2006; Ringholz et al., 2014).
The LX and epi-LX are composed of LXA4, LXB4, and Epi-LX. Epi-LX is formed from
the aspirin stimulated COX-2 product 15RHETE. LX and epi-LX are potent antiinflammatory molecules capable of decreasing neutrophil cell migration at 1nM (Fierro
et al., 2003). Treatment of rat neutrophils with LXA4 stable analogs also supported
these findings. The treated neutrophils also showed reduced adhesion molecule
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expression on rat endothelium cells. Immunohistochemical analysis confirmed this
finding, which led to less leukocyte infiltration and ultimately less inflammation (Scalia,
Gefen, Petasis, Serhan, & Lefer, 1997).
PHARMACOLGICAL INHIBITION
15-LOX-2 has been suggested to produce inflammatory mediators capable of
furthering the progression of atherosclerosis. There is enough medical need to target
15-LOX-2 for small molecule inhibition. However it appears that 5-LOX and 15-LOX or
12-LOX participate in LX formation to resolve inflammation. This turns off signals that
would result in tissue damage if left unchecked. Isoform specific inhibitors also allow for
an easy way to differentiate between 15-LOX-1 and 15-LOX-2 activity in complex
systems such as whole cells. Recently a high throughput screen has been designed
that found two potential inhibitors of 15-LOX-2 with a half maximal inhibition
concentration (IC50) in the low μM range. When other LOX and cyclooxygenases (COX)
were tested they all displayed IC50 values at least an order of magnitude higher
(Jameson et al., 2014). Now that the 15-LOX-2 structure is solved we can see the
active site and develop competitive inhibitors. If a 15-LOX-2 structure with inhibitors
bound was solved it would reveal the amino acids necessary for inhibitor binding. With
this information more potent “second generation” inhibitors can be designed.
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CHAPTER TWO
THE STRUCTURE OF HUMAN 15-LIPOXYGENASE-2 WITH A
SUBSTRATE MIMIC1
ABSTRACT
Atherosclerosis is associated with chronic inflammation occurring over decades.
The enzyme 15-lipoxygenase-2 (15-LOX-2) is highly expressed in large atherosclerotic
plaques, and its activity has been linked to the progression of macrophages to the lipidladen foam cells present in atherosclerotic plaques. We report here the crystal structure
of human 15-LOX-2 in complex with an inhibitor that appears to bind as a substrate
mimic. 15-LOX-2 contains a long loop, composed of hydrophobic amino acids, which
projects from the amino-terminal membrane-binding domain. The loop is flanked by two
Ca2-binding sites that confer Ca2-dependent membrane binding. A comparison of the
human 15-LOX-2 and 5-LOX structures reveals similarities at the active sites, as well
striking differences that can be exploited for design of isoform-selective inhibitors.
INTRODUCTION
Atherosclerosis is one of several pathologies attributed to an unchecked
inflammatory response. A hallmark of the disease is the deposition of macrophagederived foam cells in plaques that grow to restrict vascular blood flow or rupture. Either
event can culminate in one of the various manifestations of cardiovascular disease such
as heart attack or stroke. A critical component in the development of atherosclerosis is
transformation of macrophages to foam cells, a process involving the uptake of lipids

1

This chapter previously appeared as Kobe, M. J., Neau, D. B., Mitchell, C. E., Bartlett, S. G., &
Newcomer, M. E. The structure of human 15-lipoxygenase-2 with a substrate mimic. J Biol Chem. 2014;
289(12), 8562-8569. It is reprinted by permission of the American Society for Biochemistry and Molecular
Biology.
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carried by low-density lipoprotein LDL. The presence of oxidized lipids in the LDL
particles further exacerbates the process by provoking the release of inflammatory
cytokines, attracting still more macrophages to the growing lesion. Mitigation of this
inflammatory response can slow the progression of atherosclerosis.
The enzyme 15-lipoxygenase (15-LOX), which is expressed in macrophages,
has been linked to elevated levels of oxidized lipids through several experimental
approaches that include the heterologous expression of human 15-LOX in a mouse
model of hyperlipidemia (Harats et al., 2000) and pharmacological inhibition of 15-LOX
activity (Sendobry et al., 1997), (Bocan et al., 1998). Humans have two 15-LOX (Funk,
Chen, Johnson, & Zhao, 2002), designated types 1 (ALOX15A) or 2 (ALOX15B), and
the type 1 isoform was the form used in the heterologous expression studies cited
above. Mouse knock-out studies with the LOX homologue of 15-LOX-1 support a role
for ALOX15A in plaque formation (Funk, 2006). However, it is ALOX15B mRNA that is
present in human macrophages (Gertow et al., 2011; Wuest et al., 2012) isolated from
atherosclerotic plaques. Furthermore, elevated levels of ALOX15B mRNA are present in
carotid lesions derived from symptomatic, rather than asymptomatic, subjects.
ALOX15A mRNA is not detected above control levels in either case (Gertow et al.,
2011). More recently, Magnusson et al. (Magnusson et al., 2012) demonstrated that
silencing production of the ALOX15B protein in human macrophages decreased cellular
lipid accumulation, the precipitating factor in foam cell formation. Finally, 15Shydroxyeicosatetraenoic acid (HETE), derived through non-enzymatic reduction of the
product of the 15-LOX reaction, has been shown to promote formation of atherosclerotic
lesions in a mouse model system (Kotla et al., 2014).
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Lipoxygenases (LOX) are a family of iron enzymes that catalyze the peroxidation
of polyunsaturated fatty acids to generate oxylipins, which in both animals and plants
serve essential roles in signaling (Brash, 1999). The reaction proceeds via abstraction
of the hydrogen from the central carbon of a pentadiene and oxidation of the free radical
generated two carbons removed from the site of attack. Six distinct LOX have been
identified in mammals (Funk et al., 2002), and the enzymes are named according to
their product specificities. Thus, 15-LOX converts the common substrate arachidonic
acid (AA) to 15-hydroperoxyeicosatetraenoic acid (HPETE) by attack at C13 of AA,
whereas 5-LOX attacks at C7 to transform AA to 5-HPETE (and, subsequently, 5HPETE to inflammatory leukotriene A4). The question of how the AA metabolizing
enzymes are able to discriminate among the three chemically equivalent pentadienes of
AA to generate a specific HPETE isomer remains to be clarified.
The various lipid mediators of the cyclooxygenase pathway can have opposing
functions. Similarly, the LOX pathways produce either pro- or anti-inflammatory
compounds. For example, 5-LOX alone is responsible for the synthesis of the
proinflammatory leukotrienes, but anti-inflammatory lipoxins can be synthesized by the
combined activities of 15- and 5-LOX or 5- and 12-S-LOX. In addition, 15-LOX also
synthesizes the anti-inflammatory neuroprotectin D1 from docosahexaenoic acid
(Bazan, Musto, & Knott, 2011). These disparate roles for LOX products make
development of isoform-specific LOX inhibitors critical in the quest for novel
therapeutics.
LOX structures share the common framework established by Boyington et al.
(Boyington, Gaffney, & Amzel, 1993) with the soybean LOX structure. The animal
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enzymes, which generally metabolize AA rather than linoleic acid or linolenic acid,
represent a pared down version of the fold, as they are ~650 amino acids in length
rather than ~950 amino acids. However, both the plant and animal enzymes contain an
N-terminal membrane binding domain and a C-terminal catalytic domain.
We report here the crystal structure of human 15-LOX-2 in complex with a
competitive inhibitor that appears to bind as a substrate mimic. This structure reveals a
putative membrane insertion loop and two Ca2-binding sites also found at the
equivalent positions in 5-LOX. Site-directed mutagenesis supports a role for the Ca2binding sites in membrane binding, and the unique membrane insertion loop is poised to
play a role in tethering the enzyme at the bilayer. Moreover, a comparison of human 15LOX-2 and 5-LOX structures reveals significant differences in the highly conserved
active sites that can be exploited for isoform-specific inhibitor design.
EXPERIMENTAL PROCEDURES
Plasmid Construction and Protein Expression—15-LOX-2 was co-expressed
in Rossetta 2 (DE3) cells in pET Duet-1 with Escherichia coli yjgD protein. The yjgD
gene was amplified from E. coli DNA and cloned behind promoter 2 in pET Duet-1 by
digesting both vector and insert with NdeI and XhoI. The human 15-LOX-2 cDNA
obtained from the ATCC was amplified with primers containing SpeI and HindIII sites
and cloned behind promoter 1 by digesting the vector with XbaI and HindIII. After
transformation, Rosetta2 cells (Novagen) were grown as overnight cultures and then
diluted (1:100) into 500 ml volumes of Terrific broth (Alpha Biosciences) in 2-liter
Erlenmeyer flasks. After 4 h at 37 °C and 220 rpm, the speed was reduced to 150 rpm,
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and the cells were incubated an additional 27 h at 20 °C for leaky expression of 15LOX-2. Cells were harvested, pelleted, and stored at -80 °C.
Protein Purification—Cells were lysed in a mixture of Bugbuster (Invitrogen)
and Problock 2D protease inhibitor mixture (Gold Biotechnology); both were used
according to the manufacturer’s instructions. DNase I (0.2 mg/ml) (Sigma) was added,
and the suspension was processed in a French pressure cell. Insoluble material was
removed by centrifugation at 17,500 rpm for 30 min, and imidazole buffer was added to
the supernatant to a final concentration of 20 mM. The sample was syringe-filtered (0.45
μM pore size) and applied to a Co2-nitroloacetic acid column (Pierce) equilibrated with
buffer A (20 mM Tris-HCl, pH 8.0, 20 mM imidazole, 500 mM NaCl) and configured on
an Akta FPLC (GE Healthcare). Protein was eluted with a 0–100% gradient of buffer B
(20 mM Tris-HCl, pH 8.0, 200 mM imidazole, 500 mM NaCl). The major peak eluted
from the column at ~30% B. Peak fractions were pooled and concentrated with a 35kDa Amicon ultra centrifugal filtration unit (Sigma) and subsequently applied to
Superdex 200 (GE Healthcare) for gel filtration. SDS-PAGE, enzyme assays, and
product analysis confirmed that the major peak which eluted at 86 ml corresponded to
15-LOX-2. Protein was concentrated to ~10 mg/ml, flash-frozen dropwise in liquid N2,
and stored at -80 °C until use.
Crystallization—15-LOX-2 was screened for crystallization conditions with
crystal screens from Hampton and a Gryphon liquid dispenser (ARI). Conditions yielding
crystalline-like material were further screened varying pH, buffer, cryo-protectant, and
detergent. After extensive additive screening, the detergent octyltetraethylene glycol
ether (C8E4, Anatrace) proved essential for crystallization. The conditions that yielded
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diffraction quality rhombohedral crystals were 1 M NH4SO4, 0.1 M Bis-Tris, pH 5.5, 5%
glycerol, and 24 mM C8E4. Crystals were grown in hanging drops.
Diffraction Data Collection—15-LOX-2 crystals were looped from the mother
liquor and placed directly in the 100 K N2 stream of an Oxford CryoJet or plunged into
liquid N2 for shipping. Two x-ray data sets were collected at separate beamlines. The
first data set was collected to a resolution of 2.85 Å at the Gulf Coast Protein
Crystallography Consortium beamline at the Center for Advanced Microstructures and
Devices (Baton Rouge, LA). The final data set was collected to 2.65 Å at the 24ID-E
beamline of the Northeastern Collaborative Access Team at the Advanced Photon
Source (Argonne National Laboratory). This last data set was obtained from a crystal
soaked for 30 min in mother liquor supplemented with 40 mM CaCl2 prior to flashcooling in liquid N2. HKL2000 (Otwinowski et al.,1997) was used to process data
collected at the Gulf Coast Protein Crystallography Consortium beamline. XDS,
pointless, and scala were used via the RAPD processing suite of the Northeastern
Collaborative Access team to process the data collected by the Northeastern
Collaborative Access Team.
The Phenix program suite (Zwart et al., 2008) was used to perform molecular
replacement (with PHASER) and the model refinement that followed. Model building
was performed in Coot (Emsley & Cowtan, 2004). The structure of Stable-5- LOX
(Protein Data Bank 3O8Y) served as the search model for the 2.85 Å data set. The
model constructed with this data set was subsequently used as the search model for the
2.65 Å data from a CaCl2 soaked crystal. Refinement was performed with Phenix.refine.
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Enzyme Assays—Enzyme activity was monitored in an Applied Photophysics
Model SX.18MV stopped-flow spectrometer at 22 °C. Product (15hydroperoxyeicosatetraenoic acid) formation was monitored at 235 nm with a cell path
length of 0.2 cm. The enzyme concentration was 60 nm in 20 mM Tris-HCl (pH 7.5),
150 mM NaCl. Assays were performed with arachidonic acid (Cayman Chemical)
concentrations ranging from 1 to 40 M. The reported concentrations of reagents are
those in the observation cell. Each kinetic trace was the average of at least three
individual measurements. Km and Vmax value were determined by non-linear regression
analysis of a plot of velocity versus substrate concentration to Equation 1. Vmax is the
maximal velocity, S is the substrate concentration, and Km is the Michaelis constant.

𝑣=

𝑉𝑚𝑎𝑥 𝑥 [𝑆]
𝐾𝑚+[𝑆]

(Eq. 1)

Kinetic assays in the presence of C8E4 were performed to determine the mode
of inhibition. In these assays, the concentration of AA was varied between 1– 40 μM in
the presence of varying concentrations of C8E4 detergent. The enzyme concentration
was 100 nM. Nonlinear regression was used to analyze the stopped-flow data (Cleland,
1979) obtained as described above. Each data point is the average of at least three
kinetic traces. The data were fit to Equation 2, where v is the initial velocity, Vmax is the
maximal velocity, S is the substrate concentration, Km is the Michaelis constant, [I] is the
inhibitor concentration, and Ki is the inhibition constant.
𝑣=

𝑉𝑚𝑎𝑥 𝑥 [𝑆]
[ 𝐼]
)+[𝑆]
𝐾𝑚(1+𝐾𝑖

(Eq. 2)

Nanodisc Preparation—Nanodiscs were prepared with MSP1E3D1 and
phospholipids as described (Boldog, Li, & Hazelbauer, 2007),(Denisov, Grinkova,
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Lazarides, & Sligar, 2004) with minor modifications. Briefly, plasmid pMSP1E3D1
(Addgene) was expressed in Rosetta 2 cells in Terrific broth (37 °C) in the presence of
30 g/ml kanamycin. Expression was induced with 0.5 mM isopropyl 1-thio-β-Dgalactopyranoside at A600 of 1.4, and the cells were allowed to grow for 3.5 h. The
temperature was lowered to 28 °C 1 h post induction. Cells were pelleted and lysed by
sonication in 50 mM sodium phosphate (7.4), 1 mM PMSF, 1% Triton X-100. Cell debris
was pelleted, and the lysate was applied to a nickel chelate affinity column. The column
was washed with five volumes of 1) buffer C (40 mM Tris (pH 8.0), 300 mM NaCl); 2)
plus 1% Triton X-100; 3) plus 50 mM cholate; 4) buffer C, and 5) plus 50 mM imidazole.
Protein was eluted with buffer C containing 300 mM imidazole. MSP1E3D1-containing
fractions were pooled, concentrated to at least 5 mg/ml, dialyzed into nanodisc buffer
(20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5 mM EDTA), and lyophilized.
Nanodiscs were prepared from rehydrated MSP aliquots, and phospholipids were
resuspended in nanodisc buffer containing 100 mM cholate. Mixtures of phospholipids
(3:1 porcine brain PC, porcine brain PS, Avanti Polar Lipids) and MSP (160:1) in
nanodisc buffer with 25 mM cholate were incubated for 15 min at room temperature.
Cholate removal to induce nanodisc formation was accomplished with the addition of
Biobeads (0.8 g/ml, Bio-Rad) and incubation at room temperature for 2 h. Biobeads
were removed by centrifugation. Nanodisc formation and nanodisc binding by 15-LOX-2
were monitored by size exclusion chromatography on a Superose-12 column (GE
Healthcare).
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RESULTS
A Unique β-Hairpin Structure Projects from the Membrane binding
Domain—The crystal structure of human 15-LOX-2 was determined at 2.65 Å
resolution (Rwork/Rfree - 16.3/20.3; Table 1). As expected, 15-LOX-2 displays the typical
LOX fold (Fig. 3, A and B): an amino-terminal β-barrel domain, which is known as a
PLAT domain (polycystin-1-lipoxygenase α-toxin), and a significantly larger α-helical
catalytic domain.

FIGURE 3. Overlay of 15-LOX-2 and stable 5-LOX. A, schematic renderings of 15-LOX-2(green)
and stable 5-LOX (pink). Ca2+ is shown as blue spheres, and the catalytic iron is in rust. B, detail of the
difference in positioning of helix α2. Side chains from the 5-LOX segment occupy the shallower half of the
15-LOX-2 inhibitor binding site.
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TABLE 1. Diffraction data and structure refinement

The catalytic iron is positioned by the side chains of three invariant histidines (at
positions 373, 378, and 553) and the main chain carboxyl of the C terminus (Ile 676).
Human 15-LOX-2 shares 42% sequence identity with human 5-LOX and 38% or less
than that with any other LOX for which a structure has been reported (Gilbert et al.,
2011), (Choi et al., 2008), (Xu et al., 2012), (Eek et al., 2012), (Neau et al., 2009),
(Boyington et al., 1993).
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FIGURE 4. 15-LOX-2 and membrane binding. A, surface rendering of 15-LOX-2. The putative membrane
insertion loop projects from the aminoterminal PLAT domain; prolines present in the loop are colored in
red. B, rotation 90° about the horizontal, looking into the active site (C8E4, teal). The Ca2+-binding sites
(blue spheres) are on the same face of the molecule as the active site cavity, which is open to solvent. C,
upper panel: in the presence of Ca2, 15-LOX-2 co-elutes with nanodiscs. Dashed line, 0.5 mM EDTA;
solid lines, plus 2 mM CaCl2. Blue, wild-type; red, D39A/E44A; gray, D39A/E44A/D85A. Lower panel: for
reference, individual elution profiles for nanodiscs (ND; black) and 15-LOX-2 (blue); dashed line, 0.5 mM
EDTA; solid line, plus 2.0 mM Ca2+. D, detail of the Ca2+ -binding site that anchors the insertion loop.
Three main chain carbonyls, Asp85, and water (red spheres) coordinate the Ca2 (blue spheres).

TABLE 2. 15-LOX-2 kinetic parameters

LOXs are cylindrical in overall shape (~100 Å in length, ~45 Å in width), and the
PLAT domain is roughly one-third of the cylinder. In 15-LOX-2, the PLAT domain
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contains two apparent Ca2+-binding sites, the first of which (Ca-l) is located in the turn at
amino acids 39– 44. The Ca2+ in Ca-1 is coordinated by Asp39 and Glu44 and the main
chain carbonyls of Asn40 and Gly42 and a water molecule. The second site (Ca-2)
appears to stabilize a ~12-amino acid loop at Pro74–Ala86 that connects strands from the
two sides of the stacked β-sheets of the barrel. This proline-rich hydrophobic loop
projects 20 Å from the membrane-binding domain as a hairpin-like structure. The Ca-2
site, which is coordinated by Asp85, the main chain carbonyls of Ala86, Gly15, Gly17, and
a water molecule, appears to anchor the C-terminal region of the hairpin loop. The loop
is restrained by a crystal-packing contact in the crystal structure, as it is nestled at the
active site entrance of a neighboring molecule. Although this interaction may constrain
the loop in an extended fashion, the prolines at its base and within the sequence also
provide rigidity and contribute to its projection from the body of the protein. The
projection of the loop from the body of the protein is visible in the surface rendering in
Fig. 4, A and B.
Phospholipase A2 and human 5-LOX contain highly conserved calcium binding
sites in their PLAT domains (Otwinowski et al.,1997), (Gilbert et al., 2011), (Choi et al.,
2008). Although sequence homology is low, the 15-LOX-2 Ca-1 and Ca-2 binding sites
are in equivalent positions with those in 5-LOX, which displays Ca2+-dependent
membrane binding (Hammarberg, Provost, Persson, & Radmark, 2000), (Kulkarni, Das,
Funk, Murray, & Cho, 2002). The Ca2+-binding sites are positioned along one edge of
the PLAT domain, on the same face of the elongated molecule that harbors the
entrance to the catalytic site. These observations led us to test whether Asp 39, Glu44,
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and Asp85 confer Ca2+-dependent membrane binding of 15-LOX-2 (Kilty, Logan, &
Vickers, 1999).
Ca2+-dependent Membrane Binding—Ca2+-dependent membrane binding was
monitored using nanodiscs as membrane mimics. Nanodiscs with a diameter of ~110 Å
were prepared with membrane scaffold protein E3. In the absence and presence of
Ca2+ nanodiscs and 15-LOX-2 elute at ~9.7 and ~11.2 ml, respectively, on a Superose
12 column (Fig. 4C). In the absence of Ca2+, when co-incubated mixtures are applied to
the sizing column, nanodiscs, and 15-LOX-2 retain their individual elution volumes. In
contrast, with the addition of 2 mM CaCl2 to the elution buffer (which is 0.5 mM EDTA),
the LOX peak shifts to indicate co-elution with nanodiscs. This same shift was observed
in a mutant that lacks Ca-1 (D39A/ E44A). In contrast, a mutant lacking both calcium
sites (D39A/ E44A/D85A) eluted at a volume consistent with free enzyme (Fig. 4C).
Mutations of Ca2+-binding amino acids does not significantly affect enzyme activity
(Table 2). All enzymes display the same kcat, an indication that the catalytic machinery
remains intact. A detail of the Ca-2 site, which anchors the extended loop, is depicted in
Fig. 4D.
The Crystal Structure of 15-LOX-2 Reveals a Novel Inhibitor Binding in a
Substrate-like Conformation—The LOX catalytic domain is a bundle of ~20 helices.
Although LOXs share a common fold and the conformations and placement of the
majority of the helices are conserved, two distinct configurations have been described
for the region that constitutes the second helix (α2) in this domain (amino acids 178–
199 in 15-LOX-2). In 15-LOX-1 (Choi et al., 2008), 8R-LOX (Neau et al., 2009) and 12LOX (Xu et al., 2012), this region is a single α-helix that extends nearly the length of the
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catalytic domain and rims the active site cavity. In contrast, the same segment in the 5LOX (Gilbert et al., 2011) and 11R-LOX (Eek et al., 2012) structures is a meandering,
broken helix that seals off the cavity. The structure of human 15-LOX-2 displays the first
orientation: a single α-helix that helps define the periphery of the active site (see Fig. 3).
The opposite rim of the active site is formed by a structurally conserved “arched” helix
(amino acids 410– 430 in 15-LOX-2).
In the first experimental map calculated with data to 2.8 Å resolution, a
continuous electron density that could not be attributed to polypeptide was positioned
above the catalytic iron. The polyoxyethylene detergent C8E4, which was required for
diffraction quality crystals, was the most likely candidate for this density. A molecule of
C8E4 was fit into the density such that the polyoxyethylene tail was innermost and the
hydrocarbon end made its way out of the active site through the entrance portal defined
by α2 and the arched helix (Fig. 5A). The higher sigma value of the innermost electron
density most likely represents the O-rich end of the detergent, but it is not possible to
definitively determine the orientation of C8E4 in the active site. (The Protein Data Bank
file contains a second detergent modeled on the surface of the protein. Based on the
paucity of contacts it makes with the protein and the high concentration of detergent in
the crystallization buffer, this is likely a nonspecific protein-detergent interaction.)
The active site C8E4 sits in the cavity in a U-shaped conformation and is
surrounded primarily by the side chains of hydrophobic amino acids (Fig. 5B). Proximal
to the base of the “U” sits the catalytic iron, held in place by invariant histidines 373,
378, and 553. Given the shape of the cavity, we asked whether C8E4 might mimic the
conformation of the natural substrate AA and serve as a competitive inhibitor. To test
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this hypothesis, enzyme activity was assayed by monitoring the increase in absorbance
(235 nm) of HPETE at varying C8E4 concentrations. The data were fit to Equation 2.

FIGURE 5. The structure was determined in the presence of a competitive inhibitor. A, omit map
(calculated without C8E4) electron density (2Fo ~ Fc, 1σ) positioned above the active site iron is
consistent with the detergent C8E4. B, the amino acids that line the active site cavity. Shown is atomic
coloring (green, carbon; red, oxygen; blue, nitrogen), with invariant/highly-conserved amino acids in gray.
C, non-linear regression analysis of enzyme activity measured at varying inhibitor and substrate
concentrations. (.0mM; E, 0.1 mM; 1.0 mM C8E4; AA from 1 to 40μM). The points represent the observed
velocities, and the lines represent the best fit of the data to Equation 2.D, AA (purple and yellow stick
renderings; red, oxygen) can be modeled into the C8E4 density in two inversely related orientations. E,
detail of the placement of the yellow AA in D. The iron (rust) coordination sphere is filled by His-373, His378, His-553, the carboxyl terminus, and two water molecules (red). The hydrogen of the pentadiene is
poised for abstraction. The asterisk marks C13. The inverse fit of AA C7 sits at this position.

Non-linear regression analysis by the method of Cleland (Cleland, 1979)
indicates the Ki for C8E4 is 92 (±16) μM (Fig. 5C), and the inhibition is competitive. In
contrast, a satisfactory fit to the equation for non-competitive inhibition was not
obtainable.
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Modeling of AA in the Active Site—Given that C8E4 competitively inhibits 15LOX-2, we asked whether the substrate might fit into the volume occupied by the
detergent. Two orientations are possible: one with the carboxyl (“head”) innermost and
the other the hydrocarbon (“tail”) end innermost. We refined both orientations in the
C8E4 electron density with the refine ligand option in PHENIX. As can be seen from Fig.
5D, both fit into the C8E4 density, suggesting that the detergent bound structure is
similar to that of the substrate-bound structure.
Mechanistic studies have demonstrated that abstraction of the hydrogen from the
central carbon of the pentadiene and oxidation occur on opposite faces of the AA (see
Ref. (Schneider, Pratt, Porter, & Brash, 2007)). LOX structures provide a framework to
envision why this is necessary, as the same amino acids that position the catalytic iron
shield the pentadiene from molecular oxygen (Fig. 5). Crystal structures of LOX reveal
the enzyme resting state in which in Fe2+ occupies the metal binding site. The enzyme
must be activated to Fe3+ to proceed with catalysis as it is Fe3+OH- that abstracts the H
from the pentadiene (see Ref. (Schneider et al., 2007)). Note that in Fig. 3E, the Fe2+
coordination is completed with two waters. One of these waters is poised to strike a
substrate H on the central carbon of the positioned pentadiene (Fig. 5E). In the “tail first”
fit, this is C13, whereas in the head first orientation, it is C7.
Fig 6, A and B, provides a view of the relative placements of the substrate
binding site, the O2 channel (Knapp, Seebeck, & Klinman, 2001), and the catalytic iron.
Although AA can be modeled in two orientations that are “inversely” related, only one
orientation is consistent with the product specificity of 15-LOX-2. A schematic provided
Fig. 6C summarizes this information. Note the “inverse” orientations of AA on the left
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side of the figure. Both AAs are positioned such that the iron (red sphere) and O2
channel (blue peanut) are on opposite sides, but in the upper one, C13 is positioned for
attack and in the lower C7. (It is not possible for either orientation to slide deeper in the
pocket to produce another regiochemistry.) To produce 15-HPETE, hydrogen
abstraction must occur at C13, which is only possible with tail first entry. Note that
abstraction of the “back” hydrogen dictates oxygenation on the “front.” The top product
is 15-S-HPETE, and the lower product is 5-S-HEPTE. So the first orientation has both
the correct regio- and stereo-chemistries because 15-LOX-2 generates 15-S-HPETE
exclusively. Moreover, 15-LOX-2 can process phospholipid-esterified AA (Coffa &
Brash, 2004). This observation is not possible if the carboxyl end were innermost in the
site because there is no room for the phospholipid head group.

FIGURE 6. Mechanistic details are consistent with a unique orientation of AA in the active site. A,
the contour of the active site with bound C8E4 is complementary to AA in shape, and the catalytic iron
and apparent oxygen channel lie on opposite sides of the tunnel. This relationship between O2 channel
and catalytic iron is shown clearly in B. C, schematic of the two fits (Fig. 3D) of AA. The substrate can be
modeled it with its tail (top) or head deepest in the cavity (bottom). The depth of the pocket and the
orientation of the substrate determine which pentadiene is positioned for attack. In the top orientation, the
pentadiene at C13 is positioned for attack; in the lower, C7 is positioned proximal to the red sphere (iron)
behind the plane. The blue peanut represents the O2 channel slightly deeper in the active site but above
the plane. A single product is produced by each orientation: with the tail end innermost AA is transformed
to 15-S-HPETE, whereas the inverse orientation results in 5-S-HPETE.
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In conclusion, the detergent defines a cavity that can accommodate AA with no
further conformational changes. Moreover, the substrate pentadiene centered at C13 is
positioned for attack. An O2 channel lies slightly deeper in the cavity to allow O2 access
to C15. The stereochemistry of the product for this model is what is observed in vivo.
The structure is entirely consistent with tail-first entry, and inconsistent with head-first
entry of substrate.
DISCUSSION
Several lines of evidence indicate a link between 15-LOX activity and
atherosclerosis. Macrophage uptake of oxidized low-density lipoprotein promotes their
progression to lipid-loaded foam cells that contribute to atherosclerotic plaques, and
oxidized low density lipoprotein levels correlate with 15-LOX activity. A model for how
an intracellular enzyme such as 15-LOX can contribute to the oxidation of extracellular
LDL has been proposed by Hutchins and Murphy (Hutchins & Murphy, 2012). The
investigators identified 15-LOX products of the cholesterol esters of deuterated AA and
linoleic acid in macrophages incubated with lipid vesicles of cholesterol ester-esterified
arachidonic and linoleic acids. Their results led them to suggest that the hydroperoxy
acid products generated by cytosolic 15-LOX enter into extracellular pools of cholesterol
esters and phospholipids through both the continuous remodeling of cholesterol esters
and phospholipids and the constant trafficking of lipids among cellular compartments.
Two 15-lipoxygenases, with <40% sequence identity and distinct patterns of
expression and product profiles, have been identified in humans (Kilty et al., 1999),
(Brash et al., 1997). Human 15-LOX-1 generates 15-HPETE, and to a lesser extent 12HPETE using AA as a substrate, whereas the product of 15-LOX-2 with AA is
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exclusively 15-HPETE (Brash et al., 1997). Recent data implicate the 15-LOX-2 isoform
in the pathogenesis of atherosclerosis because mRNA and protein levels of this LOX
have been shown to be high in human carotid plaques (Gertow et al., 2011). In addition,
15-LOX-2 is expressed in macrophages (Wuest et al., 2012), (Danielsson et al., 2008),
(Hulten et al., 2010), and expression is regulated by hypoxia-inducible factor-1α (Hulten
et al., 2010). Moreover, knockdown of 15-LOX-2 expression in human primary
macrophages and in mice (in this case, the target was 8-LOX, the murine homologue of
15-LOX-2) decreased lipid accumulation and inflammation, hallmarks of atherosclerosis
(Magnusson et al., 2012).
Our 15-LOX-2 structure revealed a hydrophobic hairpin structure that projects
from the amino-terminal membrane binding domain. Sequence alignment indicates that
this hairpin is unique to the 15-LOX-2 isoform and could help position the enzyme at the
phospholipid bilayer. Unlike 5-LOX, 15-LOX-2 can process PC-esterified AA (Coffa &
Brash, 2004). This activity suggests a model in which translocation to the membrane
increases accessibility to substrate and a tethered enzyme could function at the
membrane interface for utilization of AA-bearing phospholipids without the need for a
lipase, or for re-esterfication of the product for the oxidized product to enter the PL
trafficking pathways.
Structures for two mammalian homologues of 15-LOX-1 (>80% identity to human
15-LOX-1, but <40% to 15-LOX-2) have been reported: one is in the absence and
presence of inhibitor (Choi et al., 2008), and the other is the catalytic domain only with
inhibitor (Xu et al., 2012). These models serve as reliable templates for human 15-LOX1. The structures of the two 15-LOX isoforms are essentially the same in terms of

34

overall fold: 15-LOX-2 superimposes with the porcine homologue with an rmsd of 1.62 Å
(552 Cα) and with the uninhibited rabbit 15-LOX-1 with an rmsd of 1.9 Å (667 Cα).
However, 15-LOX-1 lacks the extended loop at amino acids 73– 85 of 15-LOX-2.
The 15-LOX-2 Inhibitor Defines the Substrate-bound Conformation—Recall
that kinetic data indicate that C8E4 is a competitive inhibitor. In addition, AA can adopt
an equivalent U-shaped conformation to that of the bound detergent. Moreover,
placement of AA tail-first in the C8E4 electron density positions the pentadiene centered
at C13 for attack (Fig. 5, D and E). This positioning would generate the 15-S product,
consistent with the product stereochemistry observed for both 15-LOX isoforms.
Furthermore, a channel that would allow the approach of O2 to the activated pentadiene
(Knapp et al., 2001) is clearly visible in the surface rendering in Fig. 6. The competitive
inhibitor included in the porcine structure indicates a similar, but slightly deeper, cavity
to allow three more carbons past that catalytic iron and attack at C10 (the porcine
homologue generates 12-HPETE and attacks at C10). In contrast, the rabbit 15-LOX
structure with inhibitor displays a striking conformational change with ~10 Å
displacement of helix α-2 that likely is unique to the inhibitor included in the
crystallization, a conformationally restrained compound that makes contacts
inconsistent with the native substrate. Consequently, the 15-LOX-1: inhibitor structure
provides solid evidence for malleability of these active sites, and binding site plasticity
expands opportunities for isoform-specific inhibitor development.
15-LOX-2 and 5-LOX Differ in the Orientations of Their Common
Substrate—The two structures of human LOX now available, the 15-LOX-2 described
here and stable 5-LOX (Gilbert et al., 2011), can help to formulate novel strategies
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toward the development of isoform-specific inhibitors because the enzymes display
distinctly different active site cavities. A major difference between the two is that the 5LOX cavity is sealed off by the atypical placement of α2, whereas that in 15-LOX-2 is
open to solvent. The closest homologue to 15-LOX-2 in humans is 5-LOX. Recall that if
AA were positioned head-first in the 15-LOX-2 active site, it would be transformed to 5S-HPETE, the 5-LOX product. Extensive biochemical studies have led to a model in
which both cavity depth and head versus tail entry of AA combine to explain the varying
regio- and stereo-isomer specificities of LOX family members (Schneider et al., 2007).
This model predicts that AA enters 5-LOX head-first. We asked whether the head-first
entry of AA in 15-LOX-2 as illustrated in Fig. 6C (bottom) might provide insight into how
AA binds in 5-LOX. The images and schematic in Fig. 5 reveal that although the internal
portions of the LOX cavities are similar in volume, they have dissimilar chemistries.
Note that with the loss of a Glu, and the gain of 2 His, the inner portion of the 5-LOX
cavity is more positive in overall change. The amino acids that hold the catalytic iron in
place and position the pentadiene for attack are common to both active sites and
composed of invariant or highly conserved amino acids. It is not possible to compare
the cavities at the carboxyl end of the 15-LOX-2 active site because this end is tightly
corked by Phe177 and Tyr181 in 5-LOX. Although it is tempting to speculate that this end
of the site must uncork for AA to enter the 5-LOX active site, these experiments are
beyond the scope of this work.
The Murine Homologue of 15-LOX-2 Is an 8-LOX—15-S HETE (generated by
non-enzymatic reduction of 15-S-HPETE) has been shown to be the LOX product that
contributes to atherosclerosis in a murine model system (Kotla et al., 2014). However,
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silencing expression of murine ALOX15B (which produces 8-HPETE from AA rather
than 15-HPETE) mitigated plaque formation (Magnusson et al., 2012). These studies
appear to be at odds: the former indicates that it is the product of a 15-LOX that
promotes plaque formation, whereas one might infer from the latter studies that 8-HETE
should be the proinflammatory lipid mediator in the mouse model. This apparent
contradiction can be reconciled. Again, the model that proposes that LOX enzymes can
differ in terms of whether AA enters head- or tail-first (Schneider et al., 2007) is invoked
here.

FIGURE 7. The substrate binding cavities of 15-LOX-2 and stable 5-LOX. A, a surface rendering
of the inhibitor binding site in 15-LOX-2 reveals a cavity that can accommodate AA. The catalytic iron is
behind the inhibitor (orientation similar to that in Figs. 3A and 4A), and an apparent O2 channel is on the
upper face (29). B, a similar rendering of the cavity in 5-LOX with the 15-LOX-2 inhibitor superimposed.
Note that the volumes of the cavities beyond the O2 channel are similar, but that 5-LOX is “corked” above
the channel by two amino acids from α2 (Phe177, Tyr181). C, schematic of inverse orientations of AA
(black, tail first). Amino acids that line the cavity in 15-LOX-2 are listed with 5-LOX counterparts in
parentheses. Invariant amino acids are in boldface type. Amino acid changes that result in an increase in
positive change deep in the cavity of 5-LOX are highlighted in blue.
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Jisaka et al. (Jisaka et al., 2000) demonstrated that the difference in products of
15-LOX-2 and its murine counterpart 8-LOX (87% sequence identity) can be explained
by the substitution of Asp602/Val603 with Tyr/His at the equivalent positions in the 8Senzyme.

Val603 is deep in the 15-LOX-2 cavity (Fig. 7B) where the hydrocarbon end of the

substrate sits, and mutation of the murine enzyme to the human sequence (a His to Val)
at this position transformed the 8-LOX into a 15-LOX by converting an enzyme in which
AA enters head-first (as in 5-LOX) to one that enters tail first (as in 15-LOX-2).
Recall that 15-LOX-2 can metabolize PC-esterified AA. It has been reported that
murine 8-LOX can also transform phospholipid-esterified AA (Coffa & Brash, 2004).
However, the presence of the phospholipid head group makes head-first entry
impossible in the 8-LOX active site, so the murine enzyme cannot produce the 8S
isomer from PC-AA. Instead, with PC-AA as the substrate, the murine 8S-LOX is forced
to accept tail-first entry. Thus with PC-esterified substrate 8-LOX could be a de facto 15LOX. Given that 15-LOX-2 displays Ca2+ -dependent membrane binding, and the
mouse homologue includes those amino acids that confer binding and the putative
membrane insertion loop, one might predict that in vivo, the murine enzyme can
generate PC-esterified 15-HPETE that ultimately enters the cellular pool of free 15HETE. It is noteworthy that murine 8-LOXis an anomaly because the other ALOX15B
homologues generate 15-HPETE.
CONCLUDING REMARKS
In summary, we report here the structure of human 15-LOX-2. As expected 5LOX and 15-LOX-2 share a common framework, a common catalytic core, and a
common substrate. However, the enzymes generate distinct isomers of the product. A
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comparison of the structures of active site cavities of this pair of enzymes, along with an
understanding of catalytic mechanism, provides insights into substrate recognition.
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CHAPTER THREE
CONCLUSIONS
Atherosclerosis is a slowly progressive inflammatory disease that involves
multiple cells and multiple cell subtypes. Most research focuses on the monocyte
derived macrophages that infiltrate the intima although it appears that other cells are
involved. LOX are thought to be involved in multiple areas of the progression of
atherosclerosis. They are able to directly oxidize PUFA to form bioactive lipids which
can act as signaling molecules that can turn on or off expression of other proteins. 5LOX has been extensively studied and is responsible for producing leukotrienes, which
act as chemo-attractants for neutrophils. The role of 15-LOX-1 has been studied using
knockouts in both rabbit and mice models with mixed results. The role of 15-LOX-2 has
been tested using mouse cells, human cells, and plaques removed from human
patients. These results support the notion of 15-LOX-2 as an atherogenic enzyme, but
its exact function is not known. On the other hand 15-LOX-2 expression also correlates
with less inflammation in other disease states such as ulcerative colitis and cystic
fibrosis. Exactly how an intracellular enzyme can oxidize an extracellular particle is not
yet known. It seems that the two would be compartmentalized from each other
indefinitely. Murphy et al. suggests that there may be a complex lipid remodeling
system that is able to move oxidized lipids from the inside to the outside of the cell. This
would explain the results that show 15-LOX-2 as an atherogenic enzyme, but it is
possible that the eicosanoids produced are involved in atherosclerosis in an indirect
way.
15-HETE stimulates expression of CD36. This scavenging receptor is thought to
be important for the unregulated uptake of LDL. The fate of oxidized lipids is poorly
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understood. It is unclear what the exact purpose of the 15-HETE-PE or 15-HETE-PC
actually is. Studies with platelet 12-LOX and 12-HETE-PE demonstrate movement of
oxidized lipids to the outer leaflet of the plasma membrane, but it is unclear if this is the
case for esterified 15-HETE. What is understood is that exogenous 15-HETE is
esterified into mostly 15-HETE-PI which is associated with production of LXA4 an antiinflammatory oxylipin. It is currently unknown if the direct oxidation of esterified PUFA
by 15-LOX-1 or 15-LOX-2 is selective for certain phospholipids.
Regardless of the exact role of 15-LOX-2 in these processes, there is a need to
develop specific inhibitors of 15-LOX-2. At the least, researchers would be able to clarify
conflicting results on whether 15-LOX-1 or 15-LOX-2 is involved in the processes
described. The structure of 15-LOX-2 sheds light on the amino acids in the active site
of the protein. This makes the task of designing inhibitors specifically for 15-LOX-2
easier. Isoform specific inhibition allows for an easy way to design experiments to probe
the function of the enzyme. It also could allow for the discovery of a therapeutic drug to
treat lipid accumulation in atherosclerosis.
While the structure of 15-LOX-2 does not explicitly define its action in the hypoxic
macrophage, it does give us a snapshot of the protein. By using what is known in
biochemical studies of 15-LOX-2 and other LOX, the structure can be used as a
platform to forge better hypotheses about LOX in the cell.
The 15-LOX-2 structure contained the usual LOX fold seen in other LOX
structures. It has a PLAT domain and a catalytic domain. One thing that is interesting
about the 15-LOX-2 PLAT domain is that it contains a long loop that is composed of
hydrophobic amino acids and is flanked by two Ca2+ ions. By probing the function of
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this feature we found that 15-LOX-2 is able to bind membranes in the presence of
calcium. This is similar to 5-LOX although 15-LOX-2 does not migrate to the membrane
to contact an activating protein.
The active site of 15-LOX-2 contained a detergent molecule known as C8E4.
Due to the placement of the detergent molecule it was thought to be a competitive
inhibitor. This was confirmed by competitive inhibition assays. C8E4 is a flexible
inhibitor that differs from the inhibitor seen in the soybean 15-LOX structure.
Furthermore C8E4 resembles the natural curve of the recently solved 8R-LOX in
complex with it substrate AA.
Despite knowing the structure of 15-LOX-2, questions still remain about LOX
functions. It is not fully understood what all the LOX are doing when a calcium influx in
the cell occurs and cytosolic levels of AA are increased by an activated cPLA2. It
appears that 5-LOX translocates to the nuclear membrane to create LTA4 and both 15LOX-1 and 15-LOX-2 go to the plasma membrane where they can directly utilize esterlinked fatty acids. We do not know if 15-LOX-2’s unique loop is used only for membrane
insertion. Possibly, the loop could be involved in phospholipid acquisition. If the loop is
used to shuttle phospholipids from the membrane to the active site it could be a target
for small molecule inhibition. This would increase our understanding of 15-LOX-2
function in the cell, since the activities of unstimulated and stimulated 15-LOX-2 could
be separated.
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